Literature DB >> 3369972

One-year follow-up of infants with abstinence-associated seizures.

T M Doberczak1, S Shanzer, R Cutler, R T Senie, J A Loucopoulos, S R Kandall.   

Abstract

Fourteen infants with neonatal abstinence-associated seizures were assessed neurodevelopmentally during the first year of life. Despite abnormal neurologic examination results in eight of 12 infants at 2 to 4 months of age, nine of 12 infants had normal neurologic examination results at follow-up (two infants were unavailable for follow-up; one infant died of acquired immunodeficiency syndrome). Nine neonatal electroencephalograms were abnormal; seven of eight of these abnormal tracings normalized during the follow-up period. Bayley developmental scores remained normal during the first year of life and did not differ from either passively addicted infants without seizures or from published population norms. This short-term favorable prognosis for abstinence-associated seizures differs from that associated with neonatal seizures due to other causes. This observed improvement in neurologic function may be based on replenishment of neurotransmitters following transient depletion in the neonatal period.

Entities:  

Mesh:

Year:  1988        PMID: 3369972     DOI: 10.1001/archneur.1988.00520300069021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  3 in total

1.  Pharmacological treatment of neonatal opiate withdrawal: between the devil and the deep blue sea.

Authors:  Anthony Liu; Tracey Björkman; Caroline Stewart; Ralph Nanan
Journal:  Int J Pediatr       Date:  2011-05-23

2.  Poverty and Excess Length of Hospital Stay in Neonatal Opioid Withdrawal Syndrome.

Authors:  Zachary A Vesoulis; Christopher E Lust; Barbara A Cohlan; Steve M Liao; Amit M Mathur
Journal:  J Addict Med       Date:  2020 Mar/Apr       Impact factor: 4.647

3.  Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis.

Authors:  Victoria J Monnelly; Ruth Hamilton; Francesca M Chappell; Helen Mactier; James P Boardman
Journal:  Dev Med Child Neurol       Date:  2018-12-03       Impact factor: 5.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.